Overview |
bs-5793R |
Protein C inhibitor Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Rat, Dog, Cow, Sheep, Chicken |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human Protein C inhibitor |
251-350/406 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
5104 |
Cytoplasm, Secreted, Cell membrane, Extracellular matrix |
Acrosomal serine protease inhibitor; IPSP; PAI 3; PAI3; PCI; PLANH 3; PLANH3; Plasma serine protease inhibitor; Plasminogen activator inhibitor 3; Plasminogen activator inhibitor III; PROCI; Serpin A5; Serpin peptidase inhibitor clade A alpha 1 antiproteinase antitrypsin member 5; Serpin peptidase inhibitor clade A member 5; SerpinA5; IPSP_HUMAN. |
Protein C Inhibitor (PCI), a member of the serine protease inhibitor (serpin) superfamily, is abundant in plasma and other body fluids. Protein C Inhibitor inhibits a number of "arginine specific" serine proteases of the coagulation and fibrinolytic systems (including thrombin, trypsin, and activated Protein C), as well as plasma and tissue kallikreins and the sperm protease acrosin. This inhibition is regulated by glycosaminoglycans, such as heparin and heparan sulphate, and several polyanions. As well as its roles in the regulation of hemostasis and fertilisation, Protein C Inhibitor is involved in cell inflammation, proliferation, apoptosis, tumour cell migration, invasion, and metastasis. Recent studies have demonstrated an association between Protein C Inhibitor and multiple sclerosis lesions. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |